![Stomach – common complaints ,[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Más contenido relacionado
La actualidad más candente
La actualidad más candente (20)
Destacado
Destacado (13)
Similar a Rabeprazole
Similar a Rabeprazole (20)
Más de BALASUBRAMANIAM IYER
Más de BALASUBRAMANIAM IYER (20)
Último
Último (20)
Rabeprazole
- 1. Acid Peptic Disorders The Lesser Known Truths
- 5. Complications of GERD GERD complications Oesophageal erosion Oesophageal ulcer Oesophageal stricture Replacement of normal esophageal epithelium with abnormal (Barrett's) epithelium Pulmonary aspiration
- 8. Which PPI Can Promise Rapid Symptom Relief With Disease Resolution? Omeprazole Lansoprazole Pantoprazole Esomeprazole
- 10. PPI Variations OCH 3 3,5–(CH 3 ) 2 CH 3 Ome 3-CH 3 3-CH 3 R I CH 2 CH 2 CH 2 OCH 3 CH 2 CF 3 R H Rabe H Lanso R II PPI R I R R II
- 12. The Need of Today An Ideal PPI What Is That?
- 15. Rabeprazole – Milestones Launched in USA August 1999 Launched in India February 2002 Launched in 14 European countries September 1998 Launched in UK May 1998 Launched in Japan 1997
- 19. Rabeprazole – Comparative Pharmacokinetics 1 97% 1-2 Esome-prazole 1.3 98% 2.4 Panto-prazole 0.85-2 0.5-1 1.6 Half-life (hours) 94.8-97.5% 95% 97% Protein binding (%) 2-5 0.5-3.5 1.7 Time to peak plasma concentration (hours) Rabe-prazole Ome-prazole Lanso-prazole Pharmaco-kinetic Parameter
- 20. Rabeprazole – Comparative Pharmacodynamics Percent inhibition of the H+/K+-ATPase 100% 47% 66% At 10 minutes Activation time (minutes) 100% 83% 100% At 45 minutes 7.2 84 90 At a pH of 5.1 1.3 2.8 2.0 At a pH of 1.2 Rabeprazole Omeprazole Lansoprazole Pharmaco-dynamic Parameter Pharmacodynamic Parameters of the PPIs
- 21. Rabeprazole – Increased Acid suppression * Barnett JL et al, Managed Care 2001
- 22. Rabeprazole – Faster symptom relief * Barnett JL et al, Managed Care 2001
- 30. Patients' Perceptions of GERD: Evidence From the Trenches* Most persons with heartburn, experience night attacks - Nocturnal acid breakthrough [NAB]
- 31. Nocturnal Heartburn Grades in GERD: Evidence From the Trenches*
- 36. Rabeprazole in GERD -0.81 -1.10 -0.65 -0.94 119 2 -1.05 -0.87 Ome-prazole 20mg. -0.84 -0.69 Ome-prazole 20mg. 5 -1.46 -1.27 48 Rabe-prazole 20mg. Rabe-prazole 20mg. -1.21 -1.02 92 3 Day 7 Day 3 Changes in heartburn score from baseline Number of patients Heartburn episodes during screening [per week] Comparison of Rabeprazole & Omeprazole in erosive GERD: heartburn relief after 3 & 7 days
- 37. Rabeprazole for Healing of GERD Dig Dis Sci 2001 Mar;46(3):587-96 Treatment duration ranged from < or =8 weeks
- 38. Rabeprazole in Long Term GERD Maintenance Dig Dis Sci 2000;45:845-853 Treatment duration = 52 weeks
- 39. Rabeprazole In GU & DU
- 40. Rabeprazole in GU Aliment. Phramacol ther. 1998, 12:789-795 Treatment rates verified in 227 patients at 3 & 6 weeks
- 41. Rabeprazole / Omeprazole in Gastric Ulcer 86% 84% 6 80% 89% 6 67% 75% 6 83% 90% 6 44% 52% 6 65% 82% 6 59% 60% 3 Complete resolution Night time pain severity 75% 88% 3 Improvement Daytime pain severity 79% 82% 3 Improvement Frequency 61% 68% 3 Complete resolution 29% 34% 3 Complete resolution 61% 71% 3 Improvement Omeprazole 20mg Rabeprazole 20mg Week Pain Parameter Comparison of Rabeprazole & Omeprazole in GU symptom relief after 3 & 6 weeks
- 42. Rabeprazole in DU Clin Ther 2000 Mar;22(3):266-80; discussion 265 Treatment duration ranged from 4 weeks for DU
- 43. Rabeprazole In Helicobacter Pylori Infection
- 46. Rabeprazole For Special Conditions